Diagnosticos Da America S.a.BMFBOVESPA: DASA3

Dasa posted double-digit revenue and EBITDA growth in 2Q24, advancing a major hospital JV

· Issued by Diagnosticos Da America S.A.

Dasa delivered strong 2Q24 results with 10% revenue and 27% EBITDA growth, reduced leverage, and a narrowed net loss. The Amil joint venture and R$1.5B capital injection position the company for further financial strengthening and operational scale.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.